Neoplastic Disorder

13 Drugs classified under this biological system

Androgen Biosynthesis Inhibitor. Abiraterone Acetate 250 mg.
Tab 120 X 250 mg
1000 mg/d (4 tab.), once/d in comb. with oral prednisone 5 mg (twice/d for metast. CRPC and once/d for High risk mHSPC)
In comb. with prednisone for tmt. of metast. castr.-resist. prostate cancer (CRPC)
newly diagn. high risk metast. hormone-sensit. prostate
cancer (mHSPC) in adlt men in comb. with androgen depriv. ther.(ADT).  
C/I: Hypersens./Women/Sev. liver damage/In comb. with Ra-223

Monoclonal Antibody. Daratumumab 120 mg/ml.
Vial (sol. for SC inj.): 1 X 15 ml (1800 mg).
1800 mg of sol. for SC inject. over approx. 3-5 minutes accord. to the follow.
1^st – 8^th week: once/week.
9^th -24^th week :every two weeks
25^th week onwards until dis. progress.: every 4 weeks
Multiple Myeloma: in combin. with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for adults with newly diagn. multiple myeloma who are ineligible for autologous stem cell transplant.• in combin. with bortezomib, thalidomide and dexamethasone for adults with newly diagn. multiple myeloma who are eligible for autologous stem cell transplant.• in combin. with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for adults with multiple myeloma who have received at least one prior ther.• as monother. for adults with relapsed and refractory multiple myeloma, whose prior ther. included a proteasome inhib. and an immunomodul. agent and who have demonstrated disease progress. on the last ther.•for adults with multiple myeloma in combin. with pomalidomide and dexamethasone in pts. who have received at least one prior line of ther. incl. lenalidomide and a proteasome inhib. • Light chain (AL) amyloidosis: in combin. with cyclophosphamide, bortezomib and dexamethasone for adults with newly diagn. syst. AL amyloidosis.
C/I:Hypersens.

IgG2 kappa bispecific antibody. Elranatamab 40 mg/ml.
Vial with 44/76 mg  in sol. for SC inj. 40 mg/ml
Step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full dose of 76 mg weekly from week 2 to week 24
as monother. for the tmt. of adlts. with relapsed and refractory multiple myeloma, who have received at least 3 prior ther., includ. an immunomodulatory agent, a proteasome inhib., and an anti-CD38 antibody and have demonstr. dis. progress. on the last ther.
C/I: Hypersens.

CD123-directed cytotoxin. Tagraxofusp 1.15 mg/vial.
CD123-directed cytotoxin tagraxofusp
 VIAL: conc. for sol. for infus. 1X  1 mg/ml
Admin. at 12 mcg/kg IV over 15 min. 1/d on days 1 to 5 of a 21-d
cycle. Dosing period may be extend. for dose delays up to day 10 of the cycle. Cont. until dis. progress. or unaccept. tox.
Tmt. of blastic plasmacytoid dendritic cell neoplasm
(BPDCN) in adults
C/I:Hypersens.

Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml.
Vial. Pwder for sol. for inf.
5.4 mg/kg given as IV infus. once every 3 weeks (21-day cycle) until dis. progression or unacceptable tox. For gastric cancer dose is 6.4 mg/kg .Do not substitute this drug for or with trastuzumab or ado-trastuzumab emtansine.
HER2-Pos. Metast. Breast Cancer: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+ or ISH pos.) breast cancer who have received a prior anti-HER2-based regim. either:• in the metast. setting, or• in the neoadj. or adj. setting and have developed dis. recurrence during or within six months of completing ther. HER2-Low and HER2-Ultralow Metast. Breast Cancer: tmt. of adults with unresectable or metast.•Hormone receptor (HR)-pos. HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, that has progressed on one or more endocr. ther. in the metast. setting.•HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemother. in the metast. setting or developed dis. recurrence during or within 6 months of completing adj. chemother.HER2-Mutant Unresectable or Metast. Non-Small Cell Lung Cancer:tmt. of adults with unresectable or metast. non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutat., as detected by an approved test, and who have received a prior syst. ther.HER2-Pos. Locally Adv. or Metast. Gastric Cancer: tmt. of adults with locally adv. or metast. HER2-pos. (IHC 3+ or IHC 2+/ISH pos.) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regim. HER2-Positive (IHC 3+) Unresectable or Metast. Solid Tumor: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+) solid tumors who have received prior syst. tmt. and have no satisfact. alternat. options.
C/I: Hypersens.

Monoclonal Antibody. Trastuzumab 150 mg, Trastuzumab 420 mg.
Vial:Pwd. for conc. for sol for infus.
Load: 4-8 mg/kg BW
Maint. 2-6 mg/kg BW weekly or at 3 weekly interval, see lit.
Tmt. of pts. with metast. breast cancer who have tumours that overexpress HER2; 1. As a sgle. agent, for the tmt. of those pts. who have received one or more chemother. regimens for their metast. dis..2. In combin. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metastatic dis..3. In comb. with an aromatase inhib. for tmt. of postmenopausal ptt. with hne.-receptor posit. metast. breast cancer. See Lit
C/I: Hypersens. Sev. dyspnea at rest.